Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphomas in underrepresente…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Nodal Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Sonrotoclax

Snippet

Sponsor: City of Hope Medical Center | Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Status: RECRUITING